福安药业(300194) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥809,399,726.88, representing a year-on-year increase of 17.13% compared to ¥691,025,769.13 in the same period last year[5] - Net profit attributable to shareholders was ¥122,500,109.56, up 42.40% from ¥86,023,255.31 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥116,877,331.19, reflecting a 54.83% increase from ¥75,489,663.87 year-on-year[5] - Basic earnings per share increased to ¥0.10, up 42.86% from ¥0.07 in the previous year[5] - Total operating revenue for the first quarter reached ¥809,399,726.88, an increase of 17.1% compared to ¥691,025,769.13 in the previous year[23] - Net profit for the quarter was ¥122,308,127.64, representing a 38.6% increase from ¥88,250,623.91 in the prior year[24] - The company's operating profit rose to ¥146,698,587.75, a 46.8% increase from ¥99,813,121.85 year-over-year[24] - The total comprehensive income for the period was CNY 130,182,926.72, compared to CNY 89,861,967.18 in the previous year, reflecting an increase of approximately 45%[26] Cash Flow - The net cash flow from operating activities was ¥154,573,579.14, a significant improvement of 329.24% compared to a negative cash flow of -¥67,428,674.56 in the same period last year[5] - Cash flow from operating activities showed positive trends, contributing to the overall financial stability of the company[25] - The cash flow from operating activities for Q1 2024 was CNY 154,573,579.14, a significant improvement compared to a negative cash flow of CNY -67,428,674.56 in Q1 2023[27] - The total cash inflow from operating activities was CNY 777,369,502.47, compared to CNY 630,138,811.39 in the previous year, marking an increase of approximately 23.36%[27] - The company reported a decrease in cash outflows for purchasing goods and services, which amounted to CNY 155,325,679.24, down from CNY 216,810,024.43 in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,018,781,134.91, a slight increase of 0.72% from ¥5,975,931,145.19 at the end of the previous year[5] - Total liabilities decreased to ¥1,738,972,517.89 from ¥1,827,207,131.34, reflecting a reduction of 4.8%[21] - The company's equity attributable to shareholders rose to ¥4,276,081,735.08, marking a 3.17% increase from ¥4,144,805,149.99 at the end of the last year[5] - The company's equity attributable to shareholders increased to ¥4,276,081,735.08, up from ¥4,144,805,149.99, marking a growth of 3.2%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 43,612[15] - The largest shareholder, Wang Tianxiang, holds 24.00% of shares, totaling 285,499,420 shares[15] - The number of shares held by the top ten shareholders is concentrated, with the top shareholder holding 24%[15] - The company has not reported any changes in the number of shares held by the top ten shareholders due to margin trading activities[16] - There are no changes in the restricted shares held by major shareholders during the reporting period[17] Operating Costs and Expenses - The company's operating costs increased by 37.18% to ¥39,637,480.00 due to higher sales volume[10] - Total operating costs amounted to ¥701,895,237.81, up 14.4% from ¥613,468,747.82 in the same period last year[24] - Research and development expenses increased to ¥33,126,226.52, up 18.6% from ¥27,929,150.50 in the previous year[24] Investment and Financing Activities - Investment income grew by 72.39% to ¥2,540,870.00, attributed to increased returns from joint ventures[10] - The net cash flow from financing activities decreased by 124.07% to -¥10,160,580.00, primarily due to a reduction in borrowings[13] - The net cash flow from investing activities was CNY -96,044,195.79, worsening from CNY -65,274,399.29 in the same period last year[28] - The net cash flow from financing activities was CNY -101,605,830.41, a decline from a positive cash flow of CNY 422,211,794.20 in Q1 2023[28] Future Outlook - The company plans to continue investing in new product development and market expansion strategies to drive future growth[25] - The company has not disclosed any new strategies or product developments in the current report[18]